Management & Directors

The CureDM management team is comprised of talented individuals with decades of experience in major pharmaceutical and biotech companies, combined with renowned clinical experience in diabetes and metabolism as well as business professionals with successful track records. The coming together of our management team with their scientific advisors of distinction provides the direction required to bring the CureDM plan to fruition.

Loraine V. Upham
President and CEO
Chair, Board of Directors

Claresa S. Levetan, MD, F.A.C.E.
Chief Scientific Officer

Rita El-Hajj, MD, F.A.C.E.
Scientific Director

Kevin Kaster
VP of Business Development

James Revels
Acting Chief Financial Officer

Donna Morrow
Director of Development

Scientific Advisory Board

We have made it a priority to collaborate and work with experts in the field of endocrinology and drug development. To that end, we have formed a scientific advisory board comprised of industry and scientific experts who work with us on an ongoing basis to brainstorm ideas, examine potential licensing candidates and provide ongoing advice and expertise on development programs.

Our scientific advisors consist of:

Claresa Levetan, MD, F.A.C.E.

Rita El-Hajj, MD, F.A.C.E.

Lois Jovanovic, MD, F.A.C.E.

Shaoping Deng, MD, Ph.D.

Roger Nolan, Ph.D.

Jaime Davidson, MD, F.A.C.E.

Board of Directors

Collectively, the CureDM Board of Directors has many years of experience in major pharmaceutical companies, successful healthcare practices and specialty pharmaceutical start ups. The experience of CureDM’s Board of Directors, in conjunction with it’s management team and scientific advisors, provides the company with the expertise to deliver on its plan.

Loraine V. Upham

Rita El-Hajj, MD, F.A.C.E.

Stephen McLean

John H. Dillon II

Carter Meyer